Most Read Articles
Christina Lau, 03 Oct 2017

A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.

Jackey Suen, 27 Jun 2018

Gut microbiota manipulation is an exciting area of research, but a lot of questions remain regarding its clinical application and outcomes.

Inflammation potentially involved in survival in gallbladder cancer patients

15 Apr 2018

In patients with gallbladder cancer (GBC), reducing and controlling inflammation, as well as targeting relevant pathways, may improve patient outcomes and survival, according to a recent study.

In a Shanghai cohort consisting of 134 GBC patients, researchers identified eight inflammatory proteins significantly associated with survival. Elevated levels of seven of the proteins were correlated with poor overall survival, with hazard ratios (HR) ranging from 2.49 (95 percent CI, 1.41–4.41) for chemokine (C-C motif) ligand 20 (CCL20) to 3.77 (1.98–7.19) for soluble tumour necrosis factor-alpha receptor II (sTNFRII).

One inflammatory protein, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), showed a positive and significant correlation with better survival (HR for fourth vs first quartile, 0.26; 0.14–0.47; p=8.3x10-5 for trend). The survival benefit associated with TRAIL was significant only in GBC patients with late-stage disease (HR, 0.63; 0.51–0.77) but not in those with early-stage disease (HR, 1.05; 0.65–1.71).

Researchers validated the findings in a 35-patient Chile cohort, in which data were present for only seven of the original eight proteins. They found that four inflammatory proteins remained associated with poorer survival, while an elevated TRAIL concentration was still correlated with better survival.

According to researchers, proinflammatory cytokines, growth factors, cytokines, chemokines and acute-phase proteins may have a potential role in the severity and progression of GBC and warrant further research.  

“[F]urther studies among patients with GBC are required, including placebo-controlled trials of TRAIL-related anticancer drug or anti-inflammatory agents as adjuncts to other routine therapies,” they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 03 Oct 2017

A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.

Jackey Suen, 27 Jun 2018

Gut microbiota manipulation is an exciting area of research, but a lot of questions remain regarding its clinical application and outcomes.